drugset / Trial / NCT04394598
A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer
RandomizedParallel-groupSingle-blindPrevention
Summary
The study evaluates the addition of Chinese Herbal Compound Dendrobium Huoshanense Granules to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer. Half of participants will receive CRT with Dendrobium Huoshanense Granules, while the others will receive CRT with placebo. We will evaluate whether Dendrobium Huoshanense Granules can enhance the immune function and alleviate symptoms caused by the tumor and CRT .
Timeline
- Start
- 2020-03-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendrobium Huoshanense Granules | Unknown | 3 g | — |
| Background | Capecitabine | Small molecule | 625 mg/m2 | — |
| Background | Irinotecan | Small molecule | 65 mg/m2 | — |
| Background | Irinotecan | Small molecule | 80 mg/m2 | — |
Indications
No indication recorded.